Trevena Company Leadership
| TRVN Stock | USD 0.01 0.00 0.00% |
Trevena employs about 23 people. The company is managed by 10 executives with a total tenure of roughly 31 years, averaging almost 3.0 years of service per executive, having 2.3 employees per reported executive. Analysis of Trevena's management performance can provide insight into the firm performance.
| Mark Demitrack President Senior Vice President and Chief Medical Officer |
| Robert Yoder President Senior Vice President and Chief Business Officer |
Trevena Management Team Effectiveness
The company has return on total asset (ROA) of (0.6239) % which means that it has lost $0.6239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1458) %, meaning that it created substantial loss on money invested by shareholders. Trevena's management efficiency ratios could be used to measure how well Trevena manages its routine affairs as well as how well it operates its assets and liabilities.About 89.55 % of Trevena outstanding shares are held by general public with 0.48 (%) owned by insiders and only 9.97 % by institutional holders.
Some institutional investors establish a significant position in stocks such as Trevena in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Trevena, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Trevena Workforce Comparison
Trevena is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 297. Trevena holds roughly 23.0 in number of employees claiming about 8% of equities under Health Care industry.
Trevena Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Trevena insiders, such as employees or executives, is commonly permitted as long as it does not rely on Trevena's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Trevena insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Carrie Bourdow over two months ago Disposition of 143 shares by Carrie Bourdow of Trevena at 1.47 subject to Rule 16b-3 | ||
Carrie Bourdow over a year ago Disposition of 1055 shares by Carrie Bourdow of Trevena at 1.47 subject to Rule 16b-3 | ||
Moulder Leon O Jr over a year ago Acquisition by Moulder Leon O Jr of 100000 shares of Trevena at 0.43 subject to Rule 16b-3 | ||
Barry Shin over a year ago Disposition of tradable shares by Barry Shin of Trevena at 5.95 subject to Rule 16b-3 | ||
Robert Yoder over a year ago Disposition of 443 shares by Robert Yoder of Trevena at 1.55 subject to Rule 16b-3 | ||
Johnson Marvin over a year ago Acquisition by Johnson Marvin of 13700 shares of Trevena at 0.4 subject to Rule 16b-3 | ||
Mark Demitrack over a year ago Disposition of 30601 shares by Mark Demitrack of Trevena at 0.65 subject to Rule 16b-3 | ||
Barbara Yanni over a year ago Acquisition by Barbara Yanni of 100000 shares of Trevena subject to Rule 16b-3 |
Trevena Notable Stakeholders
A Trevena stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Trevena often face trade-offs trying to please all of them. Trevena's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Trevena's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Demitrack | Senior Vice President and Chief Medical Officer | Profile | |
| Robert Yoder | Senior Vice President and Chief Business Officer | Profile | |
| Carrie Bourdow | Senior Vice President Chief Commercial Officer | Profile | |
| Barry Shin | Senior CFO | Profile | |
| Joel Solomon | General VP | Profile | |
| Katrine Sutton | Principal officer | Profile | |
| Michael Catalano | Vice Marketing | Profile | |
| Howard MD | Consultant Founder | Profile | |
| Mark MD | Senior Officer | Profile | |
| Patricia Drake | Senior Officer | Profile |
About Trevena Management Performance
The success or failure of an entity such as Trevena often depends on how effective the management is. Trevena management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Trevena management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Trevena management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. Trevena operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people.
Trevena Workforce Analysis
Traditionally, organizations such as Trevena use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Trevena within its industry.Trevena Manpower Efficiency
Return on Trevena Manpower
| Revenue Per Employee | 135.9K | |
| Revenue Per Executive | 312.5K | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 4M | |
| Working Capital Per Employee | 1.2M | |
| Working Capital Per Executive | 2.8M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevena. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. To learn how to invest in Trevena Stock, please use our How to Invest in Trevena guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevena. If investors know Trevena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevena listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Trevena is measured differently than its book value, which is the value of Trevena that is recorded on the company's balance sheet. Investors also form their own opinion of Trevena's value that differs from its market value or its book value, called intrinsic value, which is Trevena's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevena's market value can be influenced by many factors that don't directly affect Trevena's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevena's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevena is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevena's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.